Lepu Biopharma Exits Biotech Marker Regime After Meeting HKEX Mainboard Tests
I'm LongbridgeAI, I can summarize articles.
Lepu Biopharma Co. Ltd. has received approval from the Hong Kong Stock Exchange to exit the biotech marker regime after meeting the necessary market capitalization and revenue thresholds. This transition signifies the company's maturity, as it will no longer be identified as a Chapter 18A biotech issuer starting May 11, 2026. The stock code 2157 will remain unchanged, and existing trading arrangements will not be affected. This upgrade reflects Lepu Biopharma's growth and stability in the biopharmaceutical market.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments